Arrowhead Pharmaceuticals, Inc. (ARWR) News

Arrowhead Pharmaceuticals, Inc. (ARWR)

Today's Latest Price: $58.88 USD

0.32 (0.55%)

Updated Oct 23 4:00pm

Add ARWR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

Filter ARWR News Items

ARWR News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ARWR News From Around the Web

Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

Global RNA Interference Market To See Astonishing Growth By 2027|Covid 19 Impact Analysis By Arcturus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals

This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of

OpenPR | September 30, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to participate in Chardan Genetic Medicines Conference

Business Wire | September 30, 2020

INO, ARWR, ADT and AXL among midday movers

Gainers: Arrowhead Pharmaceuticals (ARWR) +47%.Eastman Kodak (KODK) +39%.Myomo (MYO) +35%.Inovio Pharmaceuticals (INO) +27%.Renren (RENN) +25%.AMC Networks (AMCX) +22%.Pacific Ethanol (PEIX) +22%.Histogen (HSTO) +21%.Heat Biologics (HTBX) +16%.Ossen Innovation (OSN) +16%.Losers: Novus Therapeutics (NVUS) -17%.ADT (ADT) -13%.American Axle & Manufacturing (AXL) -12%.Forterra (FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (FRAN) -10%.Grupo Supervielle (SUPV) -9%.89bio (ETNB) -9%.Jounce Therapeutics (JNCE) -9%.Empresa Distribuidora (EDN) -6%....

Seeking Alpha | September 16, 2020

Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers

Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%....

Seeking Alpha | September 16, 2020

Arrowhead Pharma +10% on encouraging ARO-AAT data in liver disease

Arrowhead Pharmaceuticals (ARWR) jumps 10% on positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 study of ARO-AAT, the second generation investigational RNA interference (RNAi) therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency ((AATD)). The study assesses...

Seeking Alpha | September 16, 2020

Why Arrowhead Pharma's Stock Is Trading Higher Today

Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in …

Benzinga | September 16, 2020

Arrowhead Pharmaceuticals News: Why ARWR Stock Is Shooting 45% Higher Today

Arrowhead Pharmaceuticals (ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher.

InvestorPlace | September 16, 2020

Arrowhead Pharmaceuticals Is A Smart Long-Term Opportunity

Arrowhead Pharmaceuticals (ARWR) is a clinical-stage company with a broad pipeline of therapies based on its TRiM RNAi platform. While Arrowhead seems some distance from having a commercial drug approval, it is working on a kind of therapy, RNAi, that other companies have successfully commercialized. It also has partnerships where...

William Meyers on Seeking Alpha | September 11, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020

Business Wire | September 8, 2020

Eli Lilly Jardiance Data, And Other News: The Good, Bad And Ugly Of Biopharma

Eli Lilly offers positive data for Jardiance in treating cardiovascular issues Eli Lilly (LLY) reported positive data from EMPEROR-Reduced phase III trial. The study aimed to assess the potential of Jardiance in adults with heart failure with reduced ejection fraction, with and without diabetes. The drug candidate was used in...

Avisol Capital Partners on Seeking Alpha | September 4, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6241 seconds.